Andere Sprachen Longeveron Inc.

Aktien

A408R7

US54303L2034

LGVN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
1.75 ^USD	+4.79%		-8.85%	-87.13%

08.04.	Top Premarket Gainers	MT
20.03.	Longeveron führt Aktiensplit im Verhältnis 1:10 durch	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Longeveron to Present at the Planet MicroCap Showcase	25.04.
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering	18.04.
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds	17.04.
Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation	16.04.
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)	15.04.
Top Premarket Gainers	15.04.
Longeveron Announces Closing of $5.2 Million Public Offering	11.04.
Longeveron Announces Pricing of $5.25 Million Public Offering	08.04.
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals	08.04.
Top Premarket Gainers	08.04.
Longeveron to Effect 1-for-10 Reverse Stock Split	20.03.
Longeveron Announces 1-for-10 Reverse Stock Split	19.03.
Longeveron Reports Year-End 2023 Results and Provides Corporate Update	27.02.
Longeveron Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024	21.02.
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™	29.01.
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind Its Lead Investigation Product Lomecel-B	29.01.
Longeveron Closes $2.4 Million Offering	22.12.
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	21.12.
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease	20.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Longeveron Inc.

Aktien

A408R7

US54303L2034

LGVN

Andere Sprachen

Filter